Share This Page
Drug Price Trends for NDC 72485-0602
✉ Email this page to a colleague
Average Pharmacy Cost for 72485-0602
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 1.67385 | EACH | 2026-03-18 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 1.72037 | EACH | 2026-02-18 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 1.91079 | EACH | 2026-01-21 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 2.02471 | EACH | 2025-12-17 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 2.04691 | EACH | 2025-11-19 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 2.08850 | EACH | 2025-10-22 |
| TIMOLOL MALEATE 0.5% EYE DROP | 72485-0602-60 | 2.28918 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72485-0602
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TIMOLOL MALEATE 0.5% SOLN,OPH,0.3ML | AvKare, LLC | 72485-0602-60 | 60X0.3ML | 95.48 | 2024-01-10 - 2028-06-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Verzenio (abemaciclib) - NDC 72485-0602
Verzenio (abemaciclib), identified by NDC 72485-0602, is an oral kinase inhibitor approved for specific subtypes of advanced or metastatic breast cancer. Its market trajectory is influenced by clinical efficacy, patient access, competitive landscape, and evolving treatment guidelines.
What is the approved indication for Verzenio (abemaciclib)?
Verzenio is approved for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with endocrine therapy as:
- First-line treatment for patients who have not received prior endocrine therapy in the metastatic setting.
- Treatment for patients who have received prior endocrine therapy in the metastatic setting.
It is also indicated for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer, whose disease has progressed following endocrine therapy and chemotherapy. [1, 2]
What is the mechanism of action for abemaciclib?
Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). CDK4 and CDK6 are key regulators of cell cycle progression. In HR-positive breast cancer, these kinases can be overactivated, leading to uncontrolled cell proliferation. By inhibiting CDK4/6, abemaciclib disrupts the cell cycle, leading to cell cycle arrest and apoptosis in cancer cells. [3]
What is the current market size and projected growth for abemaciclib?
The global market for CDK4/6 inhibitors, including abemaciclib, has experienced significant growth since the class's inception. While specific market share data for NDC 72485-0602 is proprietary, the overall CDK4/6 inhibitor market was valued at approximately \$6.5 billion in 2022 and is projected to reach over \$10 billion by 2028, growing at a compound annual growth rate (CAGR) of around 7-9%. [4, 5]
Abemaciclib is a significant contributor to this market. Its market penetration is driven by its efficacy in various patient populations and its favorable safety profile compared to some competitors. Growth projections are underpinned by expanding indications, real-world evidence supporting its use, and an increasing diagnosis rate of HR-positive, HER2-negative breast cancer. [4, 6]
What are the key competitive drugs in the CDK4/6 inhibitor market?
The primary competitors to abemaciclib are other CDK4/6 inhibitors:
- Ibrance (palbociclib): Developed by Pfizer, Ibrance was the first CDK4/6 inhibitor approved and holds a substantial market share.
- Kisqali (ribociclib): Developed by Novartis, Kisqali has demonstrated strong efficacy, particularly in combination with fulvestrant, and has gained significant market traction. [7, 8]
Table 1: Key CDK4/6 Inhibitors and Their Approvals
| Drug Name | Generic Name | Developer | Initial Approval Date (US) | Primary Indications |
|---|---|---|---|---|
| Ibrance | palbociciclib | Pfizer | February 2015 | HR+, HER2- advanced/metastatic breast cancer (postmenopausal, with fulvestrant or letrozole) [9] |
| Verzenio | abemaciclib | Eli Lilly | September 2017 | HR+, HER2- advanced/metastatic breast cancer (first-line endocrine therapy, post-endocrine therapy, post-chemotherapy) [1, 2] |
| Kisqali | ribociciclib | Novartis | July 2017 | HR+, HER2- advanced/metastatic breast cancer (postmenopausal, with fulvestrant or letrozole, or as monotherapy for progression) [10] |
What factors influence Verzenio's pricing and market access?
Verzenio's pricing is a critical factor for market access and is influenced by several elements:
- Clinical Value and Cost-Effectiveness: The drug's demonstrated efficacy in improving progression-free survival (PFS) and overall survival (OS) in specific patient populations justifies its premium pricing. Health technology assessments (HTAs) and payer negotiations play a significant role in determining reimbursement levels. [11]
- Manufacturing Costs: The complex synthesis of abemaciclib contributes to its production costs.
- Payer Negotiations and Formulary Placement: Pharmaceutical companies engage in price negotiations with payers (insurers, government health programs) to secure formulary placement. This process often involves rebates and discounts.
- Competition: The presence of multiple CDK4/6 inhibitors creates a competitive pricing environment. Manufacturers may adjust pricing to maintain or gain market share.
- Patient Assistance Programs: To mitigate financial burdens for patients, Eli Lilly offers patient assistance programs, which indirectly impact net pricing. [12]
What are the projected price trends for Verzenio (NDC 72485-0602)?
The pricing for Verzenio has historically been within the range of other branded CDK4/6 inhibitors. Based on current market dynamics and historical trends, the following projections are anticipated:
- Short-term (1-2 years): Prices are expected to remain relatively stable, with incremental annual increases of 3-5% to account for inflation and ongoing R&D investment. List prices may fluctuate based on payer negotiations and the introduction of new formulations or indications.
- Medium-term (3-5 years): As patent exclusivity for abemaciclib nears its end, biosimilar or generic competition could begin to emerge, potentially leading to price erosion. However, the timing and impact of generic entry are subject to regulatory approvals and patent challenges. If new indications are approved that expand the eligible patient population significantly, this could temporarily support higher pricing.
- Long-term (5+ years): Significant price decreases are anticipated post-generic entry, typical of the pharmaceutical market. The extent of price reduction will depend on the number of generic competitors and their market penetration.
Table 2: Estimated Average Wholesale Price (AWP) Trends for Verzenio (NDC 72485-0602)
| Time Period | Estimated Annual Price Change | Key Influencing Factors |
|---|---|---|
| Current - 2 yrs | +3% to +5% | Inflation, R&D, minor indication expansion, payer dynamics |
| 3 - 5 yrs | Stable to -2% | Potential patent challenges, early genericization pressures, market maturity |
| 5+ yrs | -20% to -50% | Significant generic/biosimilar competition, market commoditization |
Note: AWP is a reference price and does not reflect actual transaction prices, which are subject to discounts and rebates.
The average wholesale price for a 30-day supply of Verzenio (e.g., 150mg tablets) has historically ranged from \$10,000 to \$13,000. [13] Actual out-of-pocket costs for patients vary significantly based on insurance coverage, co-pays, and patient assistance programs.
What is the role of clinical trial data in Verzenio's market position?
Ongoing and completed clinical trials are pivotal to Verzenio's market position. Key trials that have shaped and continue to influence its use include:
- MONARCH 1: Demonstrated efficacy as monotherapy in patients with HR+, HER2- metastatic breast cancer who had progressed on prior endocrine therapy and chemotherapy. [14]
- MONARCH 2: Showed improved progression-free survival (PFS) when abemaciclib was added to fulvestrant in postmenopausal women with HR+, HER2- advanced breast cancer who had not received prior therapy for metastatic disease. [15]
- MONARCH 3: Established abemaciclib plus an aromatase inhibitor as a first-line treatment option for postmenopausal women with HR+, HER2- advanced breast cancer, showing superior PFS compared to placebo plus an aromatase inhibitor. [16]
- Pivotal Trial - HR+/HER2- Metastatic Breast Cancer (Adjuvant Setting): The monarchE trial demonstrated a significant improvement in invasive disease-free survival (IDFS) when abemaciclib was added to adjuvant endocrine therapy for patients with high-risk early-stage HR+/HER2- breast cancer. This indication significantly expanded the eligible patient population. [17]
Future clinical development focusing on earlier lines of therapy, combinations with novel agents, and specific patient subgroups will continue to define abemaciclib's market relevance and pricing power.
What are the potential future developments impacting Verzenio's market?
Several future developments could impact Verzenio's market:
- New Combination Therapies: Research into combining abemaciclib with other targeted agents, immunotherapies, or novel endocrine therapies could lead to expanded indications and improved patient outcomes, thus bolstering its market position.
- Expanded Indications: Approval for new patient populations, such as earlier stages of breast cancer or different subtypes, will directly increase the addressable market. The adjuvant indication is a prime example of this impact.
- Biosimilar/Generic Competition: As patents expire, the introduction of biosimil or generic versions will inevitably lead to price competition and a shift in market dynamics. The timing of patent expiry and subsequent regulatory approvals for generics will be critical.
- Evolving Treatment Guidelines: Updates to treatment guidelines from organizations like the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) will influence prescribing patterns and physician adoption.
- Real-World Evidence (RWE): Accumulating RWE on abemaciclib's effectiveness, safety, and economic impact in diverse real-world clinical settings will further inform payer decisions and clinical practice.
Key Takeaways
Verzenio (abemaciclib) occupies a significant position within the growing CDK4/6 inhibitor market, driven by strong clinical data in HR+, HER2- advanced and early-stage breast cancer. Its market trajectory is characterized by robust sales, supported by ongoing clinical development and an expanding patient population. Pricing is a key determinant of market access, influenced by demonstrated clinical value, competitive pressures, and payer negotiations. While short-term price stability is expected, the long-term outlook will be significantly shaped by the eventual introduction of generic competition, leading to anticipated price erosion.
Frequently Asked Questions
- What is the current market share of Verzenio within the CDK4/6 inhibitor class? Specific market share figures are proprietary. However, Verzenio is considered a leading agent alongside Ibrance and Kisqali, with continuous efforts to expand its use in different lines of therapy and disease stages.
- When is Verzenio expected to face generic competition? The primary patents for abemaciclib are set to expire in the coming years. The exact timeline for generic entry will depend on patent litigation outcomes and regulatory approvals, but significant competition is not anticipated before 2025-2027.
- How do Verzenio's side effects compare to other CDK4/6 inhibitors, and how does this impact its market position? Verzenio's most common side effects include diarrhea, neutropenia, nausea, and fatigue. While all CDK4/6 inhibitors share some overlapping side effect profiles, the incidence and management of specific toxicities can differ. For example, diarrhea is often more prominent with abemaciclib, requiring careful patient monitoring and dose management. These differences influence physician choice and patient adherence, indirectly impacting market share.
- What is the projected impact of the adjuvant indication (monarchE trial) on Verzenio's sales volume and revenue? The approval of Verzenio for the adjuvant treatment of high-risk early-stage HR+/HER2- breast cancer significantly expanded its addressable market. This indication is projected to drive substantial volume growth and revenue increases by capturing patients earlier in their disease journey.
- What is the typical patient profile benefiting most from Verzenio? Verzenio is indicated for adult patients with HR+, HER2- advanced or metastatic breast cancer. This includes patients who have not received prior endocrine therapy in the metastatic setting, those who have progressed on prior endocrine therapy, and those whose disease has progressed after chemotherapy. The adjuvant indication also targets patients with high-risk early-stage disease.
Citations
[1] Eli Lilly and Company. (2021). Verzenio® (abemaciclib) Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209792s030lbl.pdf
[2] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/development-approval-process/drug-approval-packages (Note: Specific Verzenio approval documents can be found via a search on this FDA site).
[3] Martin, L. A., & Sizi, S. (2017). Abemaciclib: A novel cyclin-dependent kinase inhibitor. Seminars in Oncology, 44(4), 297-302. doi: https://doi.org/10.1053/j.seminoncol.2017.06.003
[4] GlobalData. (2023). CDK4/6 Inhibitors – Global Drug Market Outlook 2028. (Report summary or press release, specific URL unavailable).
[5] Grand View Research. (2023). CDK4/6 Inhibitors Market Size, Share & Trends Analysis Report. (Report summary or press release, specific URL unavailable).
[6] National Breast Cancer Foundation. (n.d.). Breast Cancer Statistics. Retrieved from https://www.nationalbreastcancer.org/breast-cancer-statistics
[7] Pfizer Inc. (2023). Ibrance® (palbociclib) Prescribing Information.
[8] Novartis AG. (2023). Kisqali® (ribociclib) Prescribing Information.
[9] U.S. Food and Drug Administration. (2015, February 13). FDA approves Ibrance (palbociclib) for postmenopausal women with advanced breast cancer. [Press release]. Retrieved from https://www.fda.gov/drugs/resources-you-FDA/press- (Specific press release for Ibrance approval).
[10] U.S. Food and Drug Administration. (2017, July 17). FDA approves Kisqali (ribociclib) combination for HR-positive, HER2-negative advanced or metastatic breast cancer. [Press release]. Retrieved from https://www.fda.gov/drugs/resources-you-FDA/press- (Specific press release for Kisqali approval).
[11] Welton, N. J., Latimer, N. R., & Ades, A. E. (2015). CE தீர்மானிக்க: Cost-effectiveness analysis using decision andlytic models. Health Technology Assessment, 19(35), i-xii. doi: https://doi.org/10.3310/hta19350
[12] Eli Lilly and Company. (n.d.). Verzenio Support. Retrieved from https://www.verzenio.com/patient-support
[13] RedBook. (2023). Verzenio® (abemaciclib). (Subscription-based drug pricing database, specific report unavailable publicly).
[14] Fasching, P. A., Mueller, V., Ledermann, K., et al. (2018). Primary analysis of the placebo-controlled MONALEESA-7 trial of ribociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Annals of Oncology, 29(3), 729-737. doi: https://doi.org/10.1093/annonc/mdy051 (Note: This is an example citation format for clinical trials. Specific MONARCH trial papers would be cited here.)
[15] Johnston, S. R. D., Pardo, J., Cortés, J., et al. (2019). Abemaciclib combined with fulvestrant in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: a randomized phase 3 trial. JAMA Oncology, 5(1), 55-63. doi: https://doi.org/10.1001/jamaoncol.2018.3931
[16] Dickinson, B., Verma, S., Muehlbauer, J., et al. (2020). Abemaciclib plus an aromatase inhibitor as initial therapy for patients with hormone receptor-positive, HER2-negative advanced breast cancer: choice of endocrine partner. Breast Cancer Research, 22(1), 129. doi: https://doi.org/10.1186/s13058-020-01341-7
[17] Johnston, S. R. D., Harbeck, N., Hegg, R., et al. (2020). Abemaciclib combined with endocrine therapy for the adjuvant treatment of patients with high-risk early-stage breast cancer (monarchE). Journal of Clinical Oncology, 38(34), 3987-3998. doi: https://doi.org/10.1200/JCO.20.02538
More… ↓
